VISUAL ABSTRACT
I
schemic heart disease and heart failure (HF) are the major causes of death worldwide. As such, there is an urgent need for novel therapeutic approaches that focus on different mechanisms to improve outcomes of patients suffering from ischemic heart disease and HF. Adverse remodeling of the myocardium after a myocardial infarction (MI) contributes to the severity of HF (1) , which includes alterations in myocardial energy metabolism (1, 2) . Whereas it is generally accepted that mitochondrial oxidative metabolism is compromised in the failing heart (3), there is less agreement as to whether the heart switches energy substrate preference in the failing heart (3). Impaired mitochondrial oxidative metabolism in the failing heart can decrease not only fatty acid oxidation, but also glucose oxidation (2, 4, 5) . This is accompanied by an increase in glycolysis as the remodeled heart attempts to compensate for the decrease in mitochondrial energy production (2) . This can result in an uncoupling between glycolysis and glucose oxidation, which accelerates proton production. As a result, energy has to be used for correcting acidosis-induced dysregulation of ion homeostasis (including Na þ and Ca 2þ overload) rather than supporting mechanical function, which ultimately decreases cardiac mechanical efficiency (2, 6, 7) .
Although fatty acid oxidation can be impaired in HF (due to a decrease in mitochondrial oxidative capacity) it is unclear if stimulating fatty acid oxidation is a desirable approach to treat HF. Increasing fatty acid oxidation by cardiac-specific overexpression of peroxisome proliferator-activated receptor a results in the development of cardiomyopathy (8) . Administration of peroxisome proliferator-activated receptor a agonists to isolated perfused hearts also decreases cardiac efficiency (9) . In contrast, cardiac-specific deletion of acetyl CoA carboxylase 2, which lowers malonyl CoA, accelerates fatty acid oxidation, and improves cardiac function in mice subjected to transverse aortic constriction (10) . However, this approach also markedly improves the coupling of glycolysis to glucose oxidation, resulting in a decreased lactate production. Improved coupling of glycolysis to glucose oxidation has been shown to be beneficial in reducing the symptoms of myocardial ischemia (2, 6, 7, 11, 12) . This can be achieved by inhibiting fatty acid oxidation, which increases glucose oxidation, thereby improving the coupling of glycolysis to glucose oxidation (13) . This approach benefits cardiac function (6, 11, 14) and reduces infarct size (6) in the immediate post-ischemic period.
Malonyl CoA is a key regulator of fatty acid oxidation, which inhibits carnitine palmitoyltransferase 1 (CPT1) and prevents the mitochondrial uptake of fatty acids. Myocardial malonyl CoA levels can be increased by inhibiting malonyl CoA decarboxylase (MCD), the enzyme responsible for malonyl
CoA degradation (11, 12) . Deletion of MCD (MCD À/À ) protects the hearts from ischemia/reperfusion injury and decreases infarct size (6) , which is associated with an increase in malonyl CoA levels, a decrease in fatty acid oxidation, and an increase in glucose oxidation (6, 12) . Similar findings have been recapitulated following immediate pharmacological inhibition of MCD in an experimental model of ex vivo ischemia/reperfusion injury in the heart (11, 15) . Wang et al.
Chronic MCD Inhibition Reverses Heart Dysfunction J U N E 2 0 1 9 : 3 8 5 -4 0 0 to a graded exercise test that was performed at a 5% 2) and centrifuged at 10,000 Â g. The resulting pellets were re-suspended in the ice-cold A buffer without BSA, from which, 
(50 mg/kg/day); and 5) MI þ high-dose MCD inhibitor (100 mg/kg/day), for daily oral gavage for a 4-week period. The infarct size was assessed by cutting the frozen hearts (n ¼ 7 to 8/group) into w10 mm slices followed by incubation in 1% triphenyltetrazolium chloride for 10 min at 37 C as described previously (6) . H-GLUCOSE. Glycogen was assessed in the set of hearts perfused with [5-3 H] glucose (n ¼ 6 to 9/group) via measurement of glucose content by using glucose assay kit (Sigma), as described previously (16) .
ISOENZYMES. Heart proteins (20 mg/well) were electrophoresed on 6% native gel at 4 C as described previously (20), and followed by western blot to detect isoforms of lactate dehydrogenase (LDH), of which the densitometry were analyzed using Image J-win64 software.
MEASUREMENT OF ENZYME ACTIVITIES. Citrate synthase activity (n ¼ 7 to 8/group) was measured However, the concentration that inhibits 50% was 900 nmol/l in heart mitochondria and greater than 100 mmol/l in liver mitochondria ( Figure 1E ), supporting the concept that malonyl CoA has a higher binding affinity to CPT1 in heart than in liver (24) .
To investigate if Immediate inhibition of MCD could improve cardiac function in failing hearts, invasive hemodynamics was used to assess cardiac function following a 120 min, immediate intravenous stepped-dose infusion of CBM-3001106 to 9-week post-MI rats. MI-rats exhibited a significant decrease in %EF, stroke volume, and exercise capacity, whereas an increase in left atria diameter was seen ( Table 1) . Immediate exposures of CBM-3001106 to the post-MI hearts dose-dependently increased %EF ( Figure 1F ) and stroke volume ( Figure 1G ), whereas there was decreased peak elastance ( Figure 1H ), which was accompanied by an increase in malonyl CoA levels ( Figure 1I ). In contrast, Immediate exposure to CBM-3001106 had no effects on these factors in sham hearts ( Figures 1J to 1L ), neither had effect on maximal/minimal rate of rise of left ventricular pressure (dp/dt max/min), and systolic/diastolic Since cardiac insulin resistance has been suggested to be a contributor to HF (5, 18) , the heart perfusions were performed with and without insulin to check if cardiac insulin sensitivity was altered in post-MI hearts. Absolute fatty acid oxidation rates were similar among the groups regardless of the absence or the presence of insulin ( Table 3) . Because cardiac Wang et al. 
FIGURE 3 Effect of Chronic MCD Inhibition on Cardiac Energy Metabolism in Failing Rat Hearts
Post-MI rats were treated with 50 mg/kg/day (low dose) or 100 mg/kg/day (high dose) of CBM-3001106 for 4 weeks, followed by isolated working heart perfusions.
Rates of palmitate oxidation per cardiac work (A). Rates of glycolysis per cardiac work (B). Rates of glucose oxidation per cardiac work (C). Rates of proton production (D). Expression of lactic acid dehydrogenase (LDH) isoenzymes (E) and % of LDH1 and LDH5 in total LDH (F). Citrate synthase activity (G). Mitochondrial complex I activity (H). Cardiac efficiency (I). Percent contribution of adenosine triphosphate (ATP) production from individual substrate (J).
Values represent the mean AE SD (n ¼ 3 to 10). a p < 0.05 or *p < 0.05, significantly different from sham þ vehicle or MI þ vehicle group, respectively. CS ¼ citrate synthase; other abbreviations as in Figure 1 .
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Chronic MCD Inhibition Reverses Heart Dysfunction J U N E 2 0 1 9 : 3 8 5 -4 0 0 work is a major determinant of cardiac mitochondrial oxidative metabolism (2,25), we normalized the energy metabolic rates by cardiac work. The increases in fatty acid oxidation rates ( Figure 3A ), in glycolysis rates ( Figure 3B ) and in glucose oxidation rates ( Figure 3C ) were prevented in post-MI hearts by MCD inhibition. Absolute rates of glycolysis and glucose oxidation tended to increase in the MI þ vehicle Post-MI rats were treated with 50 mg/kg/day (low dose) or 100 mg/kg/day (high dose) of CBM-3001106 for 4 weeks. Protein expression of
CD36 (A). Incorporation of [ 3 H]-palmitate into triacylglycerol (TAG) during the 1-h perfusion (B). Cytosolic GPAT activity (C). Myocardial TAG content (D). Protein expression of ATGL (E), and of SPT1 (F). Glucose incorporation into glycogen (G). Glycogen content (H). Values represent
the mean AE SD (n ¼ 4 to 7). a p < 0.05 or *p < 0.05, significantly different from sham þ vehicle or MI þ vehicle group, respectively. ATGL ¼ adipose triglyceride lipase; GPAT ¼ Glycerol-3-phosphate acyltransferase; SPT1 ¼ serine palmitoyltransferase 1; other abbreviations as in Figure 1 .
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Wang et al. Post-MI rats were treated with 50 mg/kg/day (low dose) or 100 mg/kg/day (high dose) of CBM-3001106 for 4 weeks. Protein expression of
thioredoxin-1 (Trx-1) (A). Protein expression of total forkhead box O3 (T-FOXO3), cytosolic FOXO3 (c-FOXO3) and nuclear FOXO3 (n-FOXO3) (B), as well as the densitometric analyses (C). Superoxide dismutase 2 (SOD2) activity (D). Acetylated SOD2 (Ac-SOD2) (E). Protein expression of SIRT3 (F). MCD-SOD2 interaction (G,H). Negative interaction of MCD-PDH (I).
Values represent the mean AE SD (n ¼ 3 to 7). a p < 0.05 or *p < 0.05, significantly different from sham þ vehicle or MI þ vehicle group, respectively. IgG ¼ immunoglobulin G;
group when compared to sham (Table 3) , which resulted in an increased proton production in MI þ vehicle group ( Figure 3D ), whereas the increase was prevented in MI þ high-dose group ( Figure 3D ).
An increase in the expression of M subunit of LDH
has been shown to be an indication of an increased glycolytic capacity (26) . Five isoenzymes of LDH were observed in hearts ( Figure 3E ). An increase in the expression of LDH5, the M4 isoenzyme, was evident in the post-MI hearts relative to sham ( Figure 3F ), whereas MCD inhibition reduced LDH5 but increased LDH1 ( Figure 3F) , the H4 isoenzyme, in post-MI hearts.
ATP production rates (Table 3) were unchanged among all the groups, as were citrate synthase activity ( Figure 3G ) and mitochondrial complex I activity ( Figure 3H ). However, a reduced cardiac efficiency was observed in the MI þ vehicle group relative to the sham group ( Figure 3I ), whereas the reduction was restored by MCD inhibition ( Figure 3I ).
Despite the concept that the failing heart switches from fatty acid to glucose metabolism (2), overall, fatty acid oxidation remained the predominant source of ATP production in the post-MI hearts ( Figure 3J ). In addition, SOD2, a mitochondrial antioxidant, was less active in the post-MI hearts, but the activity was enhanced by MCD inhibition ( Figure 5D ). Alterations in SOD2 activity were inversely reflected by the acetylation of SOD2 ( Figure 5E ). Neither protein expression of SIRT3 ( Figure 5F ), a mitochondrial deacetylase (30) , nor GCN5L1, a mitochondrial acetylase, was altered among the groups (data not shown). MCD has been suggested to exhibit acetyltransferase activity (31); therefore, we investigated if acetylation of SOD2 was associated with MCD through a direct interaction. Immunoprecipitation of the heart lysates revealed that SOD2 was captured by the MCD antibody ( Figure 5G) , and vice versa ( Figure 5H ), suggestive of an association between MCD and SOD2. In contrast, pyruvate dehydrogenase, a key mitochondrial enzyme modulating glucose oxidation (6), was Figure 5I ).
DISCUSSION
This study shows several important novel findings. 1)
Inhibition of MCD is able to reverse pre-existing HF as the MCD inhibitor was added after HF had already occurred in the post-MI rat ( Figures 1F to 1H and 2B) . inhibition can enhance cardiac antioxidant capacity through increasing SOD2 activity by reducing its acetylation. As a result, our data suggest a mechanism that failing heart is metabolically inefficient at using energy, while inhibiting MCD reprograms fuel use prevents proton production that improves cardiac efficiency in the post-MI heart. Thus, inhibiting fatty acid oxidation may be a promising therapeutic approach to treat HF.
It is generally assumed that the heart switches from fatty acid to glucose metabolism in the failing heart (2). If this was the case, it would not appear logical to inhibit fatty acid oxidation as an approach for improving cardiac energetics in the failing heart. It . As a result, a significant amount of cardiac ATP is shunted away from providing energy for contraction to reestablishing normal Na þ and Ca 2þ ionic homeostasis (7, 32) . The assessment of proton production rates in the current study is a technical limitation, which is not a direct measurement but a calculation from the rates of glycolysis and glucose oxidation. Our previous studies have shown that the calculated proton production from glycolysis and glucose oxidation is inversely correlated to intracellular pH, measured by using 31 -P-NMR spectroscopy, and to cardiac efficiency in post-ischemic hearts (7), whereas cardiac efficiency is improved in post-ischemic hearts by altering both the source and fate of proton (7, 32) . Kolowicz et al. (10) also observed an improved coupling of glucose metabolism with a decreased lactate production in mice with cardiac-specific deletion of acetyl CoA carboxylase 2. We further extended our understanding towards the mechanisms underlying MCD inhibitionmediated coupling of glucose metabolism and found an increased expression of LDH1 with a decreased expression of LDH5 in MI hearts post-MCD inhibition. 
Heart rate (beats/min) The use of MCD inhibitors in vivo has to consider issues such as the potential for liver steatosis due to redirecting lipids towards TAG synthesis. However, we observed that hepatic TAG content was similar among the MI groups (data not shown), which may be Figure 1E ). In addition, aged MCD À/À mice, despite elevated hepatic TAG levels, displayed a significant increase in life span of w30% than the wild-type littermates (37) .
Infarct size is a key determinant of the outcome of an acute MI (38) . Chronic MCD Inhibition Reverses Heart Dysfunction
